Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic urticaria is defined by urticarial lesions persisting at 6 weeks. The cause is not found in about 75% of cases (chronic idiopathic urticaria). The gold standard treatment consists of anti-H1 molecules. In severe cases, refractory to anti-H1, few therapeutic alternatives exist. Methotrexate, which is not expensive and often prescribed by dermatologists, has been efficiently tried in an open study on severe chronic idiopathic urticaria, and also in few case reports.
Chronic urticaria, defined by its persistence beyond 6 weeks, is a common condition (0.1% to 3% of the general population), occurring at any age. The etiology is not found in nearly 75% of cases (chronic idiopathic urticaria). Chronic idiopathic urticaria may resolve over several months or years. The quality of life of patients is usually strongly spoiled. The gold standard treatment consist of anti-H1 molecules. In severe cases, which are refractory to anti-H1, few therapeutic alternatives exist. Two studies have shown a benefit when adding to anti-H1, montelukast, anti-leukotriene, or cyclosporine. Methotrexate, which is another immunosuppressive drug, cheap and commonly prescribed by dermatologists, has been efficient in severe chronic urticaria, in an open study and in few case reports.
Methotrexate, an anti-metabolite drug which inhibits dihydrofolate reductase, is indicated in hematologic malignancies and in autoimmune diseases. It may be given by oral or parenteral administration, once a week, and requires regular monitoring of renal and hepatic function, and blood count.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group I | Active Comparator | The group I will receive the intervention : Methotrexate + anti-H1 |
|
| Group II | Placebo Comparator | The intervention in group II will include : placebo + anti-H1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methotrexate (Novatrex ®) + anti-H1 | Drug | Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks. After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18. For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with complete remission of urticaria at 18 weeks | Number of patients with complete remission of urticaria at 18 weeks, defined as no urticarial lesion 30 days before W18 | at 18 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Tolerance : clinical and biological safety | Number of patients with clinical adverse effects Number of patients with biological adverse effects | 18 weeks |
| Efficacy of the treatment in improving symptoms : pruritus |
Not provided
Inclusion Criteria:
Patients who met the diagnostic criteria for chronic idiopathic urticaria, previously treated by
Exclusion Criteria:
Differential diagnosis of chronic idiopathic urticaria (urticarial vasculitis)
Treatment with montelukast or immunosuppressive drugs during the previous month
Contraindications to methotrexate
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Annabel MARUANI, MD, PhD | University Hospital of Tours, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU BREST Morvan | Brest | 29000 | France | |||
| Chu Mondor |
Not provided
| ID | Term |
|---|---|
| D000080223 | Chronic Urticaria |
| ID | Term |
|---|---|
| D014581 | Urticaria |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008727 | Methotrexate |
| ID | Term |
|---|---|
| D000630 | Aminopterin |
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Placebo + anti-H1 | Drug | Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose. For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group. |
|
|
Number of patients with :
- pruritus At 18 weeks and 26 weeks
| 18 weeks and 26 weeks |
| Persistency of the complete remission at 26 weeks | Number of patients with persistency of the complete remission, defined as no urticarial lesion from the withdrawal of treatment until W26 | 26 weeks |
| Efficacy of the treatment in improving symptoms : outbreaks by week | - number of outbreaks by week/patient At 18 weeks and 26 weeks | 18 weeks and 26 weeks |
| Efficacy of the treatment in improving symptoms : duration of lesions | - mean +/- standard deviation duration of lesions At 18 weeks and 26 weeks | 18 weeks and 26 weeks |
| Efficacy of the treatment in improving quality of life | Mean DLQI (quality of life) score : At 18 weeks and 26 weeks | 18 weeks and 26 weeks |
| Efficacy of the treatment in improving quality of sleep | Mean score of quality of sleep (from 0 to 100) At 18 weeks and 26 weeks | 18 weeks and 26 weeks |
| Efficacy of the treatment in improving facial/cervical urticarial lesions | Number of patients with, either :
| 18 weeks and 26 weeks |
| Créteil |
| 94000 |
| France |
| Ch Le Mans | Le Mans | 72000 | France |
| CHRU LILLE Huriez | Lille | 59000 | France |
| CHRU NANCY Brabois | Nancy | 54000 | France |
| Chru Nantes | Nantes | 44000 | France |
| Hopital TENON | Paris | 75020 | France |
| CHRU POITIERS La Miléterie | Poitiers | 86000 | France |
| Chru Reims | Reims | 51000 | France |
| CHRU RENNES Pontchaillou | Rennes | 35000 | France |
| Chru Tours | Tours | 37044 | France |
| D006969 |
| Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000072471 |
| Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |